Cecilia Arana Yi, MD

hematologist and leukemia section leader

Mayo Clinic Arizona

Published Articles (1)

MDS, MECOM-Rearranged Leukemia, and BPDCN: New Data Reshaping Treatment Choices

September 15, 2026

The VERONA trial finds venetoclax adds no survival benefit in higher-risk MDS; new data illuminate outcomes in MECOM-rearranged AML and BPDCN, where transplant remains the strongest predictor of survival.